NO833257L - Farmasoeytisk preparat for hindring og behandling av ischemisk celleskade og fremgangsmaater for bruk og fremstilling derav - Google Patents
Farmasoeytisk preparat for hindring og behandling av ischemisk celleskade og fremgangsmaater for bruk og fremstilling deravInfo
- Publication number
- NO833257L NO833257L NO833257A NO833257A NO833257L NO 833257 L NO833257 L NO 833257L NO 833257 A NO833257 A NO 833257A NO 833257 A NO833257 A NO 833257A NO 833257 L NO833257 L NO 833257L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical preparation
- physiologically acceptable
- solution
- acid
- water
- Prior art date
Links
- 230000000302 ischemic effect Effects 0.000 title claims description 18
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 13
- 230000005779 cell damage Effects 0.000 title claims description 12
- 208000037887 cell injury Diseases 0.000 title claims description 12
- 238000000034 method Methods 0.000 title claims description 10
- 230000002265 prevention Effects 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title description 13
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims description 31
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 31
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 24
- 210000000056 organ Anatomy 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 230000004962 physiological condition Effects 0.000 claims description 3
- 239000008174 sterile solution Substances 0.000 claims description 3
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 claims description 2
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 2
- 229940048102 triphosphoric acid Drugs 0.000 claims 1
- 229960001456 adenosine triphosphate Drugs 0.000 description 26
- 241000700159 Rattus Species 0.000 description 19
- 230000010412 perfusion Effects 0.000 description 11
- 238000001802 infusion Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 5
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000004420 Creatine Kinase Human genes 0.000 description 4
- 108010042126 Creatine kinase Proteins 0.000 description 4
- 210000000702 aorta abdominal Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000002566 Capsicum Nutrition 0.000 description 3
- 239000006002 Pepper Substances 0.000 description 3
- 241000722363 Piper Species 0.000 description 3
- 235000016761 Piper aduncum Nutrition 0.000 description 3
- 235000017804 Piper guineense Nutrition 0.000 description 3
- 235000008184 Piper nigrum Nutrition 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003978 infusion fluid Substances 0.000 description 3
- 159000000003 magnesium salts Chemical class 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000000541 pulsatile effect Effects 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 210000002376 aorta thoracic Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- -1 inorganic bases Chemical class 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000003761 preservation solution Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229920002379 silicone rubber Polymers 0.000 description 2
- 239000004945 silicone rubber Substances 0.000 description 2
- NESXXUAWVHXRGX-UHFFFAOYSA-M sodium;1-carboxyethenyl hydrogen phosphate Chemical compound [Na+].OP(O)(=O)OC(=C)C([O-])=O NESXXUAWVHXRGX-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 238000009519 pharmacological trial Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8200252A SE8200252L (sv) | 1982-01-18 | 1982-01-18 | Farmaceutisk komposition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO833257L true NO833257L (no) | 1983-09-12 |
Family
ID=20345754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO833257A NO833257L (no) | 1982-01-18 | 1983-09-12 | Farmasoeytisk preparat for hindring og behandling av ischemisk celleskade og fremgangsmaater for bruk og fremstilling derav |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP0085033A1 (fr) |
| JP (1) | JPS58502208A (fr) |
| DK (1) | DK421283D0 (fr) |
| FI (1) | FI833320A0 (fr) |
| NO (1) | NO833257L (fr) |
| SE (1) | SE8200252L (fr) |
| WO (1) | WO1983002391A1 (fr) |
| ZA (1) | ZA83130B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8403912D0 (sv) * | 1984-07-30 | 1984-07-30 | Pharmacia Ab | Lekemedelssats eller -komposition |
| US4874882A (en) * | 1986-03-25 | 1989-10-17 | Ube Industries, Ltd. | Process for preparing monosodium phosphoenolpyruvate |
| AU618723B2 (en) * | 1986-10-06 | 1992-01-09 | University Of Virginia Alumni Patents Foundation, The | Use of an adenosine, hypoxanthine and ribose-containing solution for improved protection of the heart during surgery |
| US5070877A (en) * | 1988-08-11 | 1991-12-10 | Medco Research, Inc. | Novel method of myocardial imaging |
| JP2770175B2 (ja) * | 1988-09-27 | 1998-06-25 | 科学技術振興事業団 | 腎臓の庇護液 |
| JP2914454B2 (ja) * | 1989-03-29 | 1999-06-28 | メドコー・リサーチ・インコーポレイテッド | 血管診断助剤 |
| FR2684381B1 (fr) * | 1991-12-03 | 1995-05-05 | Nicole Bru | Composes presentant une liaison amide phosphorique ou une liaison phosphate d'enol pour leur application en tant que substance therapeutiquement active. |
| DE19603053A1 (de) * | 1996-01-29 | 1997-07-31 | Bayer Ag | Verfahren zur Herstellung von Polymeren mit wiederkehrenden Succinyl-Einheiten |
| GB9624188D0 (en) | 1996-11-21 | 1997-01-08 | Itc Research Limited | Pharmaceutical formulations |
| JPWO2008038417A1 (ja) * | 2006-09-28 | 2010-01-28 | 興和株式会社 | 循環器官用薬 |
| TW200824676A (en) * | 2006-10-24 | 2008-06-16 | Kowa Co | Cardiovascular drug |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1083911A (en) * | 1964-01-13 | 1967-09-20 | Chugai Pharmaceutical Co Ltd | Adenosine triphosphate salts of l-ornithine and process for preparing the same |
| FR3246M (fr) * | 1964-02-06 | 1965-04-12 | Pharmacodynamie Et Metabolisme | Médicaments a base d'acide phospho-énol-pyruvique. |
| DE1939008A1 (de) * | 1969-07-31 | 1971-02-11 | Zander Dr Helmut | Arzneimittelkombination zur Behandlung von Mangeldurchblutungen des Gehirns |
| US4216211A (en) * | 1977-10-31 | 1980-08-05 | The Procter & Gamble Company | Therapeutic composition |
-
1982
- 1982-01-18 SE SE8200252A patent/SE8200252L/xx not_active Application Discontinuation
-
1983
- 1983-01-10 ZA ZA83130A patent/ZA83130B/xx unknown
- 1983-01-14 WO PCT/SE1983/000003 patent/WO1983002391A1/fr active Application Filing
- 1983-01-14 JP JP83500392A patent/JPS58502208A/ja active Pending
- 1983-01-14 EP EP83850004A patent/EP0085033A1/fr not_active Withdrawn
- 1983-01-14 EP EP83900363A patent/EP0098853A1/fr not_active Withdrawn
- 1983-09-12 NO NO833257A patent/NO833257L/no unknown
- 1983-09-15 DK DK4212/83A patent/DK421283D0/da not_active Application Discontinuation
- 1983-09-16 FI FI833320A patent/FI833320A0/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58502208A (ja) | 1983-12-22 |
| EP0098853A1 (fr) | 1984-01-25 |
| SE8200252L (sv) | 1983-07-19 |
| FI833320A (fi) | 1983-09-16 |
| DK421283A (da) | 1983-09-15 |
| FI833320A0 (fi) | 1983-09-16 |
| WO1983002391A1 (fr) | 1983-07-21 |
| EP0085033A1 (fr) | 1983-08-03 |
| DK421283D0 (da) | 1983-09-15 |
| ZA83130B (en) | 1983-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4605644A (en) | Method for stimulating recovery from ischemia employing ribose and adenine | |
| Clowes Jr et al. | Circulatory and metabolic alterations associated with survival or death in peritonitis: clinical analysis of 25 cases. | |
| US6986905B1 (en) | Pharmaceutical compositions for treating and saving and the method for the preparation thereof | |
| ES2450131T3 (es) | Soluciones de diálisis esterilizadas que contienen pirofosfato | |
| NO833257L (no) | Farmasoeytisk preparat for hindring og behandling av ischemisk celleskade og fremgangsmaater for bruk og fremstilling derav | |
| US5944020A (en) | Use of fructose-1 6-diphosphate as an inotrope drug after cardiopulmonary bypass surgery | |
| EP0188595A1 (fr) | Composition medicamenteuse ou medicament sous forme de kit utilises pour la prevention et le traitement de degats causes a des cellules ischemiques, et sa preparation | |
| Kofsky et al. | Studies of myocardial protection in the immature heart: V. Safety of prolonged aortic clamping with hypocalcemic glutamate/aspartate blood cardioplegia | |
| US8563233B2 (en) | Blood substitute solution | |
| CN115813947A (zh) | 通用心脏麻痹液(多种变型) | |
| Hasselgren et al. | Failure of an increased dose of ATP-MgCl2 to improve protein synthesis and transmembrane potential in the postischemic liver | |
| Franco et al. | Effects of reperfusion after acute coronary occlusion on the beating, working heart compared to the arrested heart treated locally and globally with cardioplegia | |
| Ihnken et al. | Reversal by controlled limb reperfusion: a case report | |
| EP0665016A1 (fr) | Analeptique des fonctions cardiaques | |
| Sugishita et al. | Decreased reactive hyperemia after coronary perfusion with nonoxygenated solution | |
| CN101012240A (zh) | 磷酸肌酸精氨酸盐及其制备方法 | |
| Bloomfield et al. | A prospective trial of diaspirin cross-linked hemoglobin solution in patients after elective repair of abdominal aortic aneurysm | |
| EP0695185B1 (fr) | Utilisation d'adenosine pour la fabrication d'un medicament pour le traitement des reactions inflammatoires pulmonaires | |
| Yamagishi et al. | Effects of three purine‐related compounds on pancreatic exocrine secretion in the dog | |
| RU2815501C1 (ru) | Раствор для предтрансплантационной подготовки донорских легких | |
| US11185574B2 (en) | Protective solution for preventing or reducing reperfusion injury of the brain and the whole body | |
| Sellevold et al. | Steroids and Cardioplegia | |
| CN101007829A (zh) | 1,6－二磷酸－d－果糖酯精氨酸盐及其药物用途 | |
| JPH05286861A (ja) | 低血圧維持剤 | |
| Rao et al. | Effects of metabolic stimulation on cardiac allograft recovery |